Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020575 · ClinicalTrials.gov registry record · Phase 1
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
A Phase 1 study of Metastatic Breast Cancer, sponsored by Minerva Biotechnologies Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 69
- Enrollment target
- 1
- Study location
NCT04020575 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Minerva Biotechnologies Corporation. The registered enrollment target is 69 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04020575, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Minerva Biotechnologies Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 69 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\*).
Conditions Studied
Interventions
- BIOLOGICAL huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells
- BIOLOGICAL huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2035-01-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04020575
The ClinicalTrials.gov registry entry for NCT04020575 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (66% lower). The listed sponsor is Minerva Biotechnologies Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells is the first listed.
NCT04020575 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04020575 about?
NCT04020575 is a clinical study titled "Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)". Phase I/II study of adoptive immunotherapy for advanced MUC1\* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1\*).
What is the current status of trial NCT04020575?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2020-01-15. Estimated completion is 2035-01-15.
What conditions does trial NCT04020575 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT04020575?
The interventions under investigation include: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells (BIOLOGICAL), huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D (BIOLOGICAL).
Who is sponsoring clinical trial NCT04020575?
This trial is sponsored by Minerva Biotechnologies Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04020575 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.